MYRIAD GENETICS, INC. Payments of Debt Issuance Costs
MYRIAD GENETICS, INC. (MYGN) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-28
- MYRIAD GENETICS, INC. payments of debt issuance costs for the quarter ending 2022-12-31 was $0.00.
- MYRIAD GENETICS, INC. payments of debt issuance costs for the quarter ending 2022-09-30 was $700.00K.
- MYRIAD GENETICS, INC. payments of debt issuance costs for the quarter ending 2022-06-30 was $0.00.
- MYRIAD GENETICS, INC. payments of debt issuance costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. payments of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MYRIAD GENETICS, INC. payments of debt issuance costs for fiscal 2023 was $1.70M, a 142.86% increase from fiscal 2022.
- MYRIAD GENETICS, INC. payments of debt issuance costs for fiscal 2022 was $700.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $1.70M 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $700.00K derived: sum of 2 quarters · filed 2025-02-28 | $700.00K derived: sum of 3 quarters · filed 2025-02-28 | $700.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $700.00K derived: sum of 2 quarters · filed 2022-11-02 | $700.00K 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $1.20M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.20M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-06 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.00M derived: sum of 2 quarters · filed 2021-11-04 | $1.00M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.00M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |